IRLAB Therapeutics
31.12.2021 10:51:35 CET | ACCESS Newswire | Press release
GOTHENBURG, SE / ACCESSWIRE / December 31, 2021 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)
IRLAB (Nasdaq Stockholm: IRLAB A). Martin Nicklasson has announced his intention to leave the board in January 2022. The background to this decision is his new role as chairman of the board in another company.
According to IRLAB's articles of association, the board shall consist of at least three (3) and at most (10) members. When Nicklasson leaves the board, it will consist of five (5) members, and will thus continue to fulfill this requirement up to the next annual general meeting in May 2022, when a new board shall be chosen.
"On behalf of the board and shareholders I would like to extend a hearty thank-you to Martin for his valuable input to board activities this past year," says Gunnar Olsson, IRLAB's chairman of the board. "2021 has been a transformative period in IRLAB's development. Our successful license deal with mesdopetam and the regulatory approvals for the start of the Phase IIb study with pirepemat have given us a completely new basis for achieving IRLAB's long-term goals."
For more information
Gunnar Olsson, Chair of the board
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se
About IRLAB
IRLAB is a Swedish research and development company that focuses on discovery and development of novel treatments in Parkinson's disease. The company's most advanced drug candidates, Mesdopetam (IRL790), licensed to Ipsen, and Pirepemat (IRL752), have completed Phase IIa studies and are designed to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through its proprietary research platform, the Integrative Screening Process (ISP), IRLAB has discovered and developed all its projects within Parkinson's disease and will have an ability to also discover drug candidates for other disorders of the central nervous system (CNS), where large and growing medical needs exist. In addition to the Phase IIb clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phases. IRLAB is listed on Nasdaq Stockholm Main Market. More information is found on www.irlab.se.
Attachments
Board member leaves IRLAB for another assignment
SOURCE: IRLAB Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/680352/Board-Member-Leaves-IRLAB-for-Another-Assignment
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Driving the World's Leading Supply Chains: 9 OMP Customers Named to The 2026 Gartner Top 2518.6.2026 15:00:00 CEST | Press release
As global leaders move from firefighting to foresight, OMP celebrates the enterprise visionaries scaling decision-driven intelligence at the speed of change. ANTWERPEN, BE / ACCESS Newswire / June 18, 2026 / OMP, a leading AI-powered provider of supply chain planning solutions, extends its congratulations to the 9 customer organizations recognized in the newly released Gartner® Supply Chain Top 25 and Masters for 2026. Now in its 22nd year, the Gartner Supply Chain Top 25 remains the definitive benchmark for supply chain excellence, evaluating global enterprises on financial performance, ESG initiatives, and community opinion. This year's rankings point to three capabilities separating market leaders: building an autonomous workforce where people and intelligent systems collaborate on decisions, adopting network-centric strategies that treat supply chain design as a continuous, adaptive process, and orchestrating decisions end-to-end across increasingly complex ecosystems. OMP's custom
U.S. Polo Assn. Unveils Spring-Summer 2027 Collection at the 110th Edition of Pitti Immagine Uomo18.6.2026 13:00:00 CEST | Press release
Global Sports Brand Puts the Iconic Polo Shirt at the Center of its Pitti Uomo Experience FLORENCE, IT AND WEST PALM BEACH, FL / ACCESS Newswire / June 18, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), returned to Florence, Italy, for Pitti Immagine Uomo 110 to present The Polo Shirt: An Icon Born from the Game™ and its Spring-Summer 2027 Global Collection showcasing a modern, global expression of the sport-inspired lifestyle. The collection includes classic, sport-inspired apparel, footwear, bags, and accessories that blend authentic American-inspired sports style with European craftsmanship. 1) Polo Shirt Installation for U.S. Polo Assn. Booth at Pitti Uomo 110 in Florence, Italy 2) U.S. Polo Assn. Booth at Pitti Uomo 110 featuring The Polo Shirt: An Icon Born from the Game 3) Pitti Uomo 110 Attendees Crowd the U.S. Polo Assn. Booth U.S. Polo Assn.'s exhibit at Pitti Uomo is taking place from June 16 to 19, 2026, at Booth 32 Cavanigli
Deadline Extended for 2026 Semmelweis-Richter Journalism Award Applications18.6.2026 11:30:00 CEST | Press release
Following strong interest and numerous requests, the application deadline for the 2026 Semmelweis-Richter Journalism Award has been extended by two weeks. Submissions are now accepted until June 23, 2026, 23:59 CET. BUDAPEST, HU / ACCESS Newswire / June 18, 2026 / Building on the success of its inaugural edition, the award continues to recognise outstanding journalism that contributes to public understanding of key health issues and fosters informed discussion across Europe. The initiative is organised by Semmelweis University, Hungary's leading medical and health sciences institution, in partnership with Gedeon Richter, a Hungary-based, innovation-driven specialty pharmaceutical company. Entries are invited in two categories: Women's Health and Pharmaceutical Strategies and Innovation, the latter placing particular emphasis on cardiovascular therapies. The organisers welcome high-quality reporting that sheds light on pressing or underrepresented health topics, addresses stigma, and su
LiberNovo Announces Early Launch of Prime Sale, Featuring Limited Omni Bundle Flash Deals Starting Today18.6.2026 04:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / June 17, 2026 / LiberNovo today opened early access to its 2026 Prime Sale, with up to 49% off and a limited run of flash-deal bundles built around the original LiberNovo Omni. Early access is live now, and the full sale runs June 23 through July 11. LiberNovo makes dynamic ergonomic chairs, the first designed to respond to your body as it moves. Instead of locking you into one fixed posture, the dynamic support system keeps the neck support, backrest, armrests, and seat moving together as you shift, lean, and recline. Prime Sale - Omni Series Clearance Deals The original LiberNovo Omni is available at Prime Sale clearance pricing while stocks last, with prices starting as low as €939 (49% off in the EU) and £869 (46% off in the UK), representing significant savings for consumers. The original LiberNovo Omni - the first dynamic ergonomic chair - features an eight-panel Bionic FlexFit Backrest and automatic armrests that move with you through every shif
U.S. Air Force Awards GA-ASI Production Contract for FQ-42A CCA18.6.2026 00:10:00 CEST | Press release
Company Will Produce Service's New Uncrewed Combat Jets SAN DIEGO, CA / ACCESS Newswire / June 17, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has received a production contract from the U.S. Air Force (USAF) for the FQ-42A Collaborative Combat Aircraft (CCA). The initial order is a significant milestone, beginning the delivery of production aircraft to the warfighter. GA-ASI designed, developed and flight-tested FQ-42A on an accelerated schedule unlike any fighter in recent history. "This is an exciting day for our company and the nation," said company President David R. Alexander. "Moving to production on FQ-42A is the result of an extraordinary partnership and many years of investments between General Atomics and the U.S. Air Force. We've been preparing for this order, and manufacturing is already well underway." The FQ-42A is a purpose-built, uncrewed fighter developed as part of ongoing investment in next-generation semi-autonomous combat aircraft. The aircraft's mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom